HomeGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
Previous close
$8.66
Day range
$8.61 - $8.97
Year range
$5.30 - $12.15
Market cap
6.77B USD
Avg Volume
1.58M
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 1.82B | 9.28% |
Operating expense | 391.79M | 2.42% |
Net income | 14.84M | -61.12% |
Net profit margin | 0.82 | -64.19% |
Earnings per share | 0.15 | 65.37% |
EBITDA | 367.38M | 9.48% |
Effective tax rate | 63.03% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.26B | 317.59% |
Total assets | 22.29B | 4.01% |
Total liabilities | 14.00B | 5.96% |
Total equity | 8.30B | — |
Shares outstanding | 679.63M | — |
Price to book | 1.05 | — |
Return on assets | 3.33% | — |
Return on capital | 3.74% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 14.84M | -61.12% |
Cash from operations | 252.86M | 1,438.03% |
Cash from investing | 1.35B | 2,708.00% |
Cash from financing | 59.44M | -67.86% |
Net change in cash | 1.66B | 1,358.23% |
Free cash flow | 1.65B | 7,696.47% |
About
Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories. Wikipedia
Founded
Nov 18, 1940
Website
Employees
23,505
